SUMMARY: Icosavax, Inc., a member of the AstraZeneca Group (LSE/STO/Nasdaq: AZN), is a biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. Icosavax's VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific v...
SUMMARY: Icosavax, Inc., a member of the AstraZeneca Group (LSE/STO/Nasdaq: AZN), is a biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. Icosavax's VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific v...
